Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
CSPC Pharma weighs up diet drug for bigger bottom line
After three years of sluggish growth, the company has delivered higher quarterly earnings from sales of existing drugs and is exploring new avenues in the weight-loss business Key Takeaways: CSPC…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
Akeso marks profit milestone with swift rights issue
9926.HK
